NCT03375320 2026-04-13Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 3 FDA
NCT02420691 2020-10-30Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginM.D. Anderson Cancer CenterPhase 2 Completed21 enrolled 14 charts